A Phase 3 interventional study of Benralizumab in Asthma, sponsored by AstraZeneca. Completed at 144 sites in 17 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-06-06.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 7th largest by enrollment, is one of 2 that started in 2018, is one of 20 in phase 3, and was the 24th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 598 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 59th largest by enrollment of the 248 interventional ones that give a count, is one of 8 that started in 2018, is one of 121 in phase 3, and was the 237th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller medications.
This is an open-label, multicenter study designed to evaluate efficacy and safety of reducing daily oral corticosteroid (OCS) use after initiation of 30 mg dose of benralizumab administered subcutaneously (SC) in patients with severe eosinophilic asthma receiving high-dose inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) and OCS with or without additional asthma controller(s).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab subcutaneous injection
Biological: Benralizumab
Benralizumab subcutaneous injection
Patients Who Achieve 100% Reduction in Daily OCS Dose
Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
Time frame: Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)
Patients Who Achieve 100% Reduction or a Daily OCS Dose of <=5mg
Patients who achieve 100% reduction or a daily OCS dose of \<=5mg, if reason for no further OCS reduction is Adrenal Insufficiency, that are sustained over at least 4 weeks without worsening of asthma
Time frame: Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)
Patients Who Achieve a Daily OCS of ≤5mg
Patients who achieve a daily OCS dose of ≤5 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma
Time frame: Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)
Patients Who Achieve a ≥90%, ≥75%, and ≥50% Reduction in Daily OCS Dose
Patients who achieve a ≥90%, ≥75%, and ≥50% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
Time frame: Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)
Change From Baseline in Average Daily OCS Dose (mg)
Change from baseline in average daily OCS dose (mg) from start of OCS reduction to end of the OCS reduction phase
Time frame: Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)
Patients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy
Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
Time frame: from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.
Patients Who Achieve a Daily OCS Dose of ≤5 mg at the End of the Long Term Follow up Substudy
Patients who achieve a daily OCS dose of ≤5 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma
Time frame: from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.
Patients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy
Patients who achieve a ≥90%, ≥75%, and ≥50% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
Time frame: from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.
Change in Daily OCS Dose (mg) From Main Study Baseline to the End of the Long Term Follow up Substudy
Change in average daily OCS dose (mg) from main study baseline to the end of the long term follow up substudy
Time frame: from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.
705 participants provided informed consent and were assigned a unique enrollment number prior to screening. Of the 705 patients screened, 598 (84.8%) were eligible to receive Benralizumab 30 mg and entered the study. All 598 (100%) patients received the study drug. 195 of the 538 patients who completed the main study treatment enrolled into PONENTE Long Term Follow Up Substudy.
| Milestone | Benra 30 mg |
|---|---|
| Started | 598 |
| Completed | 563 |
| Not completed | 35 |
| Withdrew: Withdrawal by subject | 10 |
| Withdrew: Adverse event | 7 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Other | 3 |
| Withdrew: Death | 2 |
| Withdrew: Failure to meet inclusion/exclusion criteria | 2 |
| Milestone | Benra 30 mg |
|---|---|
| Started | 563 |
| Completed | 536 |
| Not completed | 27 |
| Withdrew: Adverse event | 4 |
| Withdrew: Death | 3 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Pregnancy | 2 |
| Withdrew: Protocol violation | 11 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Other | 3 |
| Milestone | Benra 30 mg |
|---|---|
| Started | 195 |
| Asthma treatment as per healthcare provider discretion | 195 |
| >=50% any biologic | 78 |
| >=50% benra | 69 |
| Completed | 195 |
| Not completed | 0 |
Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
| Participants | Benra 30 mg |
|---|---|
| Patients Who Achieve 100% Reduction in Daily OCS Dose | 376 |
Patients who achieve 100% reduction or a daily OCS dose of \<=5mg, if reason for no further OCS reduction is Adrenal Insufficiency, that are sustained over at least 4 weeks without worsening of asthma
| Participants | Benra 30 mg |
|---|---|
| Patients Who Achieve 100% Reduction or a Daily OCS Dose of <=5mg | 490 |
Patients who achieve a daily OCS dose of ≤5 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma
| Participants | Benra 30 mg |
|---|---|
| Patients Who Achieve a Daily OCS of ≤5mg | 547 |
Patients who achieve a ≥90%, ≥75%, and ≥50% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
| Participants | Benra 30 mg |
|---|---|
| ≥90% reduction | 383 |
| ≥75% reduction | 412 |
| ≥50% reduction | 489 |
Change from baseline in average daily OCS dose (mg) from start of OCS reduction to end of the OCS reduction phase
| mg | Benra 30 mg |
|---|---|
| Change From Baseline in Average Daily OCS Dose (mg) | -8.50 (-9.10 to -7.90) |
Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
| Participants | Asthma Treatment as Per Healthcare Provider Discretion | >=50% Any Biologic | >=50% Benra |
|---|---|---|---|
| Patients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy | 138 | 60 | 54 |
Patients who achieve a daily OCS dose of ≤5 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma
| Participants | Asthma Treatment as Per Healthcare Provider Discretion | >=50% Any Biologic | >=50% Benra |
|---|---|---|---|
| Patients Who Achieve a Daily OCS Dose of ≤5 mg at the End of the Long Term Follow up Substudy | 177 | 72 | 65 |
Patients who achieve a ≥90%, ≥75%, and ≥50% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
| Participants | Asthma Treatment as Per Healthcare Provider Discretion | >=50% Any Biologic | >=50% Benra |
|---|---|---|---|
| >=90% reduction | 141 | 61 | 55 |
| >=75% reduction | 151 | 64 | 58 |
| >=50% reduction | 172 | 71 | 64 |
| >0% reduction | 175 | 72 | 65 |
Change in average daily OCS dose (mg) from main study baseline to the end of the long term follow up substudy
| mg | Asthma Treatment as Per Healthcare Provider Discretion | >=50% Any Biologic | >=50% Benra |
|---|---|---|---|
| Change in Daily OCS Dose (mg) From Main Study Baseline to the End of the Long Term Follow up Substudy | -10.01 (-11.26 to -8.76) | -10.28 (-12.16 to -8.41) | -10.8 (-12.85 to -8.75) |
Collected over Main study: From first dose of study drug until end of study, with an average of 405 days. Substudy: on-study period, between the date of informed consent for the substudy and the last available visit or contact for a patient, with an average of 18 days.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benra 30 mg | 5/598 (0.8%) | 89/598 (14.9%) | 181/598 (30.3%) |
| Asthma Treatment as Per Healthcare Provider Discretion | 0/195 (0%) | 0/195 (0%) | 0/195 (0%) |
| >=50% Any Biologic | 0/78 (0%) | 0/78 (0%) | 0/78 (0%) |
| >=50% Benra | 0/69 (0%) | 0/69 (0%) | 0/69 (0%) |
| Event | Benra 30 mg | Asthma Treatment as Per Healthcare Provider Discretion | >=50% Any Biologic | >=50% Benra |
|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 23/598 | 0/195 | 0/78 | 0/69 |
| PneumoniaInfections and infestations | 11/598 | 0/195 | 0/78 | 0/69 |
| InfluenzaInfections and infestations | 5/598 | 0/195 | 0/78 | 0/69 |
| Acute myocardial infarctionCardiac disorders | 4/598 | 0/195 | 0/78 | 0/69 |
| SepsisInfections and infestations | 3/598 | 0/195 | 0/78 | 0/69 |
| Angina unstableCardiac disorders | 2/598 | 0/195 | 0/78 | 0/69 |
| Cardiac arrestCardiac disorders | 2/598 | 0/195 | 0/78 | 0/69 |
| IleusGastrointestinal disorders | 2/598 | 0/195 | 0/78 | 0/69 |
| Chronic sinusitisInfections and infestations | 2/598 | 0/195 | 0/78 | 0/69 |
| DiverticulitisInfections and infestations | 2/598 | 0/195 | 0/78 | 0/69 |
| Event | Benra 30 mg | Asthma Treatment as Per Healthcare Provider Discretion | >=50% Any Biologic | >=50% Benra |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 64/598 | 0/195 | 0/78 | 0/69 |
| Influenza like illnessGeneral disorders | 33/598 | 0/195 | 0/78 | 0/69 |
| HeadacheNervous system disorders | 29/598 | 0/195 | 0/78 | 0/69 |
| Viral upper respiratory tract infectionInfections and infestations | 28/598 | 0/195 | 0/78 | 0/69 |
| Upper respiratory tract infectionInfections and infestations | 25/598 | 0/195 | 0/78 | 0/69 |
| HypertensionVascular disorders | 21/598 | 0/195 | 0/78 | 0/69 |
| SinusitisInfections and infestations | 19/598 | 0/195 | 0/78 | 0/69 |
Full analysis set
| Age, Continuous(years) | Benra 30 mg |
|---|---|
| Mean | 53.3 ± 13.59 |
| Sex: Female, Male(Participants) | Benra 30 mg |
|---|---|
| Female | 383 |
| Male | 215 |
| Race/Ethnicity, Customized(Participants) | Benra 30 mg |
|---|---|
| White | 475 |
| Black or African American | 26 |
| Asian | 29 |
| Native Hawaiian or other Pacific Islander | 1 |
| American Indian or Alaska Native | 46 |
| Other | 12 |
Showing the first 100 of 144 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2018 to primary completion in Apr 2021, 32 months.
Results were first posted in Jun 2022, 1 year 2 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 32 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab